Savient names John Hamill as CFO Savient Pharmaceuticals announced the appointment of John P. Hamill as SVP & Chief Financial Officer, effective today. Most recently, Hamill served as CFO of PharmaNet Development Group.
News For SVNT From The Last 14 Days
Check below for free stories on SVNT the last two weeks.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: Actuant (ATU) downgraded to Neutral from Buy at SunTrust... Aruba Networks (ARUN) downgraded to Perform from Outperform at Oppenheimer... CAE (CAE) downgraded to Sector Perform from Outperform at RBC Capital... City Holding (CHCO) downgraded to Market Perform from Outperform at Keefe Bruyette... Deere (DE) downgraded to Sell from Neutral at Goldman... Disney (DIS) downgraded to Neutral from Overweight at Atlantic Equities... HSBC (HBC) downgraded to Neutral from Outperform at Exane BNP Paribas... L Brands (LTD) downgraded to Underperform from Hold at Jefferies... Manning & Napier (MN) downgraded to Underperform from Neutral at BofA/Merrill... MeadWestvaco (MWV) downgraded to Underperform from Sector Perform at RBC Capital... National Grid (NGG) downgraded to Neutral from Outperform at Exane BNP Paribas... Savient (SVNT) downgraded to Market Perform from Outperform at William Blair... Stryker (SYK) downgraded to Reduce from Neutral at SunTrust... TRW Automotive (TRW) downgraded to Hold from Buy at Deutsche Bank... Universal Health (UHS) downgraded to Neutral from Positive at Susquehanna... Williams-Sonoma (WSM) downgraded to Neutral from Buy at BofA/Merrill... Zimmer (ZMH) downgraded to Reduce from Neutral at SunTrust... Aviva (AV) downgraded to Underperform from Sector Perform at RBC Capital... Pandora (P) downgraded to Hold from Buy at Maxim... Lumos Networks (LMOS) downgraded to Neutral from Buy at DA Davidson... Brocade (BRCD) downgraded to Underperform from Market Perform at William Blair... Applied Materials (AMAT) downgraded to Neutral from Buy at DA Davidson... Cosi (COSI) downgraded to Market Perform from Outperform at Northland Securities.
Savient downgraded to Market Perform from Outperform at William Blair William Blair downgraded Savient Pharmaceuticals citing disappointing Krystexxa sales and lowered its price target for shares to $1 from $2.
Subscribe for More Information